Clinical Trial Update: Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating single-agent obinutuzumab for relapsed/refractory Post-transplant Lymphoproliferative Disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Post-transplant Lymphoproliferative Disorder, PTLD | Phase 2 | Status: WITHDRAWN